Regeneron, Zai Lab to Develop REGN1979 Antibody
April 08 2020 - 6:45AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Zai Lab Ltd. on Wednesday
said they agreed to collaborate on the development and
commercialization of Regeneron's REGN1979 bispecific antibody in
mainland China, Hong Kong, Taiwan and Macau.
The companies said Regeneron will receive a $30 million upfront
payment and is eligible to receive up to $160 million in milestone
payments.
Regeneron and Zai said the collaboration will support global
clinical development for REGN1979, starting with the ongoing phase
2 program in B-cell non-Hodgkin lymphoma.
Regeneron, a Tarrytown, N.Y., biotechnology company, said
REGN1979 is the most advanced investigational bispecific monoclonal
antibody from its bispecific platform and is designed to trigger
tumor killing by linking and activating a cytotoxic T-cell to a
lymphoma cell.
Shanghai biopharmaceutical company, Zai will contribute to the
global development costs for REGN1979 for certain trials and will
receive the rights to develop and exclusively commercialize the
antibody in oncology in mainland China, Hong Kong, Taiwan and
Macau, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 08, 2020 06:30 ET (10:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024